- Scoring System Can Avoid Unnecessary Surgery For Clogged Arteries
- Anemia In Pregnancy Increases Risk Of Heart Defects
- Urinary Incontinence Linked To Heart Disease Risk In Women
- Opioids Tough To Prescribe For Legitimate Patients, Doctors Say
- Cancer Prevention Not Yet Recovered From Pandemic-Era Declines, Report Says
- Virtual Singing Programs Boost Mood, Well-Being Of Isolated Seniors
- FDA Approves Dupixent for Chronic Spontaneous Urticaria
- Some OB/GYNS Stay in States With Abortion Bans, Despite Legal Risks
- Teen Cannabis Use Rises in Canada After Edibles Are Legalized
- Federal Prosecutor Questions Medical Journals Over Alleged Bias
Rapamune Approved for Rare Lung Disease

Rapamune (sirolimus) has been approved by the U.S. Food and Drug Administration to treat a rare, progressive lung disease that mostly affects women of childbearing age.
Lymphangioleiomyomatosis (LAM) is characterized by the unusual growth of smooth-muscle cells among lung tissue. This can block normal airflow in the lungs and hinder delivery of oxygen to the rest of the body. The very rare disease affects only two to five women per million women globally, the FDA said in a news release.
The drug was first approved in 1999 to help prevent organ rejection among people aged 13 and older who had kidney transplant. It’s now the first drug approved to treat LAM.
The FDA said it granted the drug’s maker, Philadelphia-based Pfizer, financial incentives as part of a program to encourage development of medications to treat rare conditions.
The most common side effects reported during clinical testing included mouth and lip ulcers, diarrhea, abdominal pain, nausea, sore throat, acne and chest pain. More serious adverse effects included allergic-like reactions and swelling.
More information
Visit the FDA to learn more about this approval.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.